Sage Therapeutics announced the discontinuation of its experimental drug, Dalzanemdor (SAGE-718), intended for the treatment of mild cognitive impairment in Parkinson's disease following its failure to meet the primary endpoint in a Phase 2 study. The drug did not show statistically significant differences compared to placebo, leading to a decision to halt further development. This development negatively impacted Sage Therapeutics' stock, which fell by approximately 20% and was down 4% before the bell. Additionally, SAGE-718 is also being studied for potential treatment in Alzheimer's and Huntington's disease.
$SAGE shares dipped 20% today following news that the company's experimental medicine for cognition failed in a Parkinson's disease study https://t.co/Co2ubXGdnp
Sage Therapeutics is terminating the development of its drug dalzanemdor in Parkinson’s disease after a mid-stage test ended in disappointment. https://t.co/R5X5u2HduV
Sage’s cognition drug fails in Parkinson’s study https://t.co/OuinSRaecE by @realJacobBell $SAGE - 21%
Sage Therapeutics scraps plans for Parkinson's drug after mid-stage failure https://t.co/274HnppoJX https://t.co/6gbCcIjGNB
SAGE-718 dalzanemdor Ph 2 readout in Parkinson’s data out today $SAGE 😲-20% right on the mark (see quoted posted from 3/25) https://t.co/qFUmkcAgzs https://t.co/w5pxbjm8nl
Sage Therapeutics’ stock plunges as Parkinson’s drug trial disappoints https://t.co/MMDtJiHKt6
$SAGE (-18.7% pre) Sage drops after mid-stage setback for Parkinson’s disease candidate - SA https://t.co/DGt3j79D0b
Sage Therapeutics said on Wednesday it will stop development of its experimental drug to treat Parkinson's disease after it failed a mid-stage study, sending the company's shares down 4% before the bell. https://t.co/lQHsxUMSRY https://t.co/lQHsxUMSRY
$SAGE pipeline setback. SAGE-718 failed to improve cognition vs placebo in Parkinson's ph2 study Studies of -718 in Alzheimer's and Huntington's reading out later this year. https://t.co/94jutgZWzA
$SAGE Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson’s Disease. - Dalzanemdor did not show statistically significant differences versus placebo on the primary endpoint